RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.54
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$38.35

17 Jan
2025

0.810

OPEN

$38.02

2.16%

HIGH

$38.39

752,668

LOW

$38.02

TARGET
$41.083 7.1% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 144.6 xxx
DPS (cps) 32.7 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 26.8 xxx
Dividend Yield 0.8% xxx
Div Pay Ratio(%) 22.6% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.93%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.80

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/11 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx106.0
DPS All xxxxxxxxxxxxxxx29.6
Sales/Revenue xxxxxxxxxxxxxxx7,150.0 M
Book Value Per Share xxxxxxxxxxxxxxx495.8
Net Operating Cash Flow xxxxxxxxxxxxxxx2,138.4 M
Net Profit Margin xxxxxxxxxxxxxxx21.79 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx23.10 %
Return on Invested Capital xxxxxxxxxxxxxxx18.26 %
Return on Assets xxxxxxxxxxxxxxx15.25 %
Return on Equity xxxxxxxxxxxxxxx23.10 %
Return on Total Capital xxxxxxxxxxxxxxx24.60 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,555.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx53 M
Long Term Debt xxxxxxxxxxxxxxx1,256 M
Total Debt xxxxxxxxxxxxxxx1,309 M
Goodwill - Gross xxxxxxxxxxxxxxx4,256 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx357 M
Price To Book Value xxxxxxxxxxxxxxx5.87

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx175.3 M
Capex % of Sales xxxxxxxxxxxxxxx2.45 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,169 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,869 M
Research & Development xxxxxxxxxxxxxxx469 M
Investments - Total xxxxxxxxxxxxxxx227 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

29/10/2024

3

Neutral

-

-

UBS observes ResMed reported better than expected sales at 1Q25 results with gross margin meeting expectations and lower than forecast costs compared to consensus.

The analyst lifts FY25 gross margin forecast to 59.9% from 58.3%. The FY26 estimate rises to 60.3% from 58.8% as this quarter's margin is viewed as achievable going forward.

With a slight upward revision in the broker's sales forecasts, the EPS estimates rise 4% in FY25 and 5% in FY26. ResMed is expected to be net-cash positive by end of FY25 and is expected to retain share buybacks of US$75m per quarter.

Neutral rating unchanged. Target price rises to US$250 from US$225.

FORECAST
UBS forecasts a full year FY25 dividend of 33.01 cents and EPS of 148.49 cents.
UBS forecasts a full year FY26 dividend of 34.69 cents and EPS of 167.20 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

xx/xx/xxxx

1

xx-xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

31/10/2024

1

Overweight

$42.18

9.99%

Wilsons maintains an Overweight rating on ResMed, upgrading its target to $42.18 from $40.25. At a 20x enterprise to earnings ratio, the stock has done nothing other than" recapture what it should never have lost, amid last year’s GLP-1Ra driven nonsense".

In 16 years of covering the stock, Wilsons has never seen secular demand drivers to match what’s happening now externally and internally. The remainder of 2024 can still throw up some opportunistic GLP-1 "panic" to take advantage of, the broker suggests.

Competitively, expanding the availability of mask resupply beyond Brightree’s home medical equipment network and talking candidly about ASP increases was an absolute "flex" on the Sep Q earnings call, Wilsons suggests.

FORECAST
Wilsons forecasts a full year FY25 dividend of 32.56 cents and EPS of 143.31 cents.
Wilsons forecasts a full year FY26 dividend of 33.77 cents and EPS of 150.77 cents.

Jarden

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

RMD STOCK CHART

FNArena News on RMD

1
Australian Broker Call *Extra* Edition – Jan 20, 2025

10:31 AM - Daily Market Reports
2
Weekly Ratings, Targets, Forecast Changes – 17-01-25

10:00 AM - Weekly Reports
3
Rudi’s View: Best Buys & Convictions For 2025

Jan 16 2025 - Rudi's View
4
Rudi’s View: All-Weather Portfolio In 2024

Jan 15 2025 - Rudi's View
5
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
2
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
3
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
4
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
5
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
6
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
7
ResMed Silences The Doubters

Apr 29 2024 - Australia
8
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
9
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
10
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia